Skip to main content

Investors

Roche’s Half-Year Results 2026 Presentation

Roche has published its Half-Year Results for 2026 prior to the opening of the Swiss Stock Exchange on Thursday, 23 July 2026.

Please click here to watch the replay
Presentation download
Presentation with appendix download

A blue-gloved hand delicately holds a small pink container with a QR code. Nearby are green, blue, and yellow containers on a white surface, indicating a scientific setting.

Roche’s Virtual ADA Investor Event

Roche has hosted a virtual event on Monday, 8 June 2026.

Please click here to watch the replay
Presentation download

A gloved hand in a lab coat holds a small, clear vial against a blurred background of lab equipment, conveying a scientific and clinical setting.

Roche’s Investor Event at ASCO 2026

Roche has hosted an Investor Event at ASCO on Tuesday, 2 June 2026.

Please click here to watch the replay
Presentation download

Decorative illustration

Investors at a glance

+11%

Core earnings per share growth at Constant Exchange Rates in 2025 (Core EPS 19.46 CHF - diluted)

39 million

patients were treated with Roche medicines in 2025

31 billion

Roche Diagnostic tests were delivered to customers worldwide in 2025

Product Development Pipeline
Read the letter to shareholders

Our two divisions are focusing jointly on three disease areas that will account for almost 50% of the global disease burden by 2035: cancer, cardiovascular-metabolic diseases and neurological diseases.

Portrait of Thomas Schinecker

Dr Thomas Schinecker

CEO Roche Group

Investor updates

View all updates
View ad-hoc announcements
Subscribe

Upcoming Investor events

View all events

Roche Half Year Results 2026 (virtual event)

Investors

July 23, 2026 at 14:00 CEST | Basel, Switzerland

Read more
Add to calendar

TD Cowen Hot Wheels Tour (virtual event)

Investors

August 11, 2026 at 08:00 EDT | New York, US

Read more
Add to calendar

Guggenheim Conference Call Series "Bridging the Gap" (virtual event)

Investors

September 04, 2026 at 16:00 CEST

Read more
Add to calendar

J.P. Morgan CEO Conference Call Series (virtual event)

Investors

September 07, 2026 at 16:00 CEST | Basel, CH

Read more
Add to calendar

Goldman Sachs 23rd Annual European Medtech and Healthcare Services Conference

Investors

September 09, 2026 at 08:00 BST | London, UK

Read more
Add to calendar

Bernstein - Premium Review Conference

Investors

September 10, 2026 at 08:00 BST | London, UK

Read more
Add to calendar

BofA Global Healthcare Conference

Investors

September 22, 2026 at 08:00 BST | London, UK

Read more
Add to calendar

Barclays EU MedTech & Life Sciences Investor Trip 2026 (virtual event)

Investors

September 25, 2026 at 10:00 CEST | Basel, CH

Read more
Add to calendar

Roche Pharma Day 2026

Investors

September 28, 2026 at 09:00 BST | London UK

Read more
Add to calendar

Latest reports

A person wearing purple gloves holds a test tube, preparing for a laboratory experiment or analysis.

Half-year report 2026

Investors
decorative image

Annual report 2025

Investors

Investor relations team contacts

Do you need to get in touch with us? Reach out to our investor relations team with your enquiries.

View investor contact detail

Discover More

  • Roche Diagnostics news

    Follow the most recent updates from our Diagnostics business

  • Genentech

    Genentech has been delivering on the promise of biotechnology for over 35 years.

  • Sustainability at Roche

    About Roche

    At Roche, sustainability means operating with a long-term mindset – ensuring more people can benefit from our science and innovation today without compromising the world they will live in tomorrow.

  • Positions, policies & downloads

    About Roche

    Download our policies, guidelines, positions and other documents.

  • Frequently asked questions

    Investors

    We answer the Roche investors-related most frequently asked questions

  • Partnering

    Innovation

    At Roche Partnering, we are passionate about science: yours and ours. Through partnerships, we hope that together we can build a better future with medicines that make a real difference to patients.